Oncotarget

Research Papers:

Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway

Zhaohua Zhang, Luan Zhang, Chao Sun, Feng Kong, Jue Wang, Qian Xin, Wen Jiang, Kaili Li, Ou Chen and Yun Luan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:63430-63441. https://doi.org/10.18632/oncotarget.18825

Metrics: PDF 2537 views  |   HTML 3372 views  |   ?  


Abstract

Zhaohua Zhang1, Luan Zhang1, Chao Sun2, Feng Kong2, Jue Wang2, Qian Xin2, Wen Jiang2, Kaili Li2, Ou Chen2 and Yun Luan2

1Department of Pediatrics, The Second Hospital of Shandong University, Jinan, China

2Central Research Laboratory, The Second Hospital of Shandong University, Jinan, China

Correspondence to:

Yun Luan, email: [email protected]

Keywords: baicalin, pulmonary hypertension, vascular remodeling, NF-κB, BMP

Received: January 23, 2017     Accepted: June 01, 2017     Published: June 28, 2017

ABSTRACT

Baicalin, a flavonoid compound extracted from roots of Scutellaria baicalensis Georgi (huang qin), it has been shown to effectively attenuates pulmonary hypertension (PH), however, the potential mechanism remains unexplored. In this study, we investigated the potential mechanism of baicalin on monocrotaline (MCT)-induced PH in rats. The results showed that baicalin attenuated lung damage in PH rat model through inhibiting the pulmonary arterial smooth muscle cell proliferation and induction of cells apoptosis. Furthermore, we demonstrated that baicalin inhibition the expression of nuclear factor-κB (NF-κB) p65 and bone morphogenetic protein (BMP) antagonists gremlin-1, but increased the expression of inhibitor of NF-κB (I-κBα), BMPR2, BMP-4, BMP-9 and Smad1/5/8. Additionally, baicalin suppression endothelial-to-mesenchymal transition in PH lung tissue. Collectively, we confirmed that baicalin via inhibition of NF-κB signaling to further activation of BMP signaling to have a therapeutic effect on PH and providing a promising therapeutic strategy for PH.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18825